Key clinical point: For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), adding polatuzumab vedotin to bendamustine and rituximab can improve complete response rates and extend overall survival.
Major finding: Patients treated with a combination of polatuzumab vedotin, bendamustine, and rituximab had significantly longer median overall survival than patients who received bendamustine and rituximab (12.4 vs. 4.7 months; P = .002).
Study details: The phase 1b/2 trial involved 107 patients with relapsed/refractory DLBCL.
Disclosures: The study was funded by F. Hoffmann-La Roche and Genentech. The investigators reported additional relationships with AbbVie, Kite Pharma, Lundbeck, and others.
Sehn LH et al. J Clin Oncol. 2019 Nov 6. doi: 10.1200/JCO.19.00172.